(PharmaNewsWire.Com, June 22, 2017 ) T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Cluster of Differentiation 86 or CD86 or B7-2 is a protein expressed on antigen-presenting cells. It plays a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy.
Report Highlights
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase I and Preclinical stages are 2, 1 and 3 respectively. Report covers products from therapy areas Immunology, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones and Ophthalmology which include indications Rheumatoid Arthritis, Alopecia, Autoimmune Disorders, Dermatomyositis, Giant Cell Arteritis, Graft Versus Host Disease (GVHD) , Granulomatosis with Polyangiitis (Wegener Polyangiitis) , Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA) , Polymyositis/Idiopathic Inflammatory Myopathy, Psoriatic Arthritis, Sicca Syndrome (Sjogren) , Systemic Idiopathic Juvenile Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) , Takayasu Arteritis, Transplant Rejection, Uveitis and Vitiligo.
The latest report T Lymphocyte Activation Antigen CD86 - Pipeline Review, H1 2017, outlays comprehensive information on the T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
- The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - The report reviews T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics and enlists all their major and minor projects - The report assesses T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles 3SBio Inc Bristol-Myers Squibb Company KAHR medical Ltd Momenta Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by 3SBio Inc, H1 2017 Pipeline by Bristol-Myers Squibb Company, H1 2017 Pipeline by KAHR medical Ltd, H1 2017 Pipeline by Momenta Pharmaceuticals Inc, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: